Recent News

• 09.17.2025 - TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 09.08.2025 - TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
• 09.02.2025 - TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
• 08.28.2025 - TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
• 08.19.2025 - TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
• 06.24.2025 - TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

Recent Filings

• 09.10.2025 - 8-K Current report
• 09.10.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 8-K/A Current report
• 09.05.2025 - D Notice of Exempt Offering of Securities
• 09.02.2025 - 8-K Current report
• 09.02.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 06.06.2025 - 8-K Current report
• 05.19.2025 - DEFR14A Revised definitive proxy soliciting materials